Molecular Mechanism in the Disruption of Chronic Traumatic Encephalopathy-Related R3-R4 Tau Protofibril by Quercetin and Gallic Acid: Similarities and Differences.
暂无分享,去创建一个
[1] F. J. Luque,et al. Three to Tango: Inhibitory Effect of Quercetin and Apigenin on Acetylcholinesterase, Amyloid-β Aggregation and Acetylcholinesterase-Amyloid Interaction , 2022, Pharmaceutics.
[2] Bikash R. Sahoo,et al. Free Gangliosides Can Alter Amyloid-β Aggregation. , 2022, The journal of physical chemistry letters.
[3] O. Rolinski,et al. Impact of the Flavonoid Quercetin on β-Amyloid Aggregation Revealed by Intrinsic Fluorescence , 2022, The journal of physical chemistry. B.
[4] Hope Pan,et al. De novo designed protein inhibitors of amyloid aggregation and seeding , 2022, Proceedings of the National Academy of Sciences of the United States of America.
[5] P. Derreumaux,et al. Molecular Dynamics Simulations of the Tau Amyloid Fibril Core Dimer at the Surface of a Lipid Bilayer Model: I. In Alzheimer's Disease. , 2022, The journal of physical chemistry. B.
[6] P. Derreumaux,et al. Molecular Dynamics Simulations of the Tau R3-R4 Domain Monomer in the Bulk Solution and at the Surface of a Lipid Bilayer Model. , 2022, The journal of physical chemistry. B.
[7] Yuejuan Zheng,et al. Quercitrin improved cognitive impairment through inhibiting inflammation induced by microglia in Alzheimer’s disease mice , 2022, Neuroreport.
[8] S. Perrett,et al. Distinct lipid membrane-mediated pathways of Tau assembly revealed by single-molecule analysis. , 2022, Nanoscale.
[9] Son Tung Ngo,et al. Effect of Cholesterol Molecules on Aβ1-42 Wild-Type and Mutants Trimers , 2022, Molecules.
[10] H. Hsieh-Li,et al. Flavones 7,8-DHF, Quercetin, and Apigenin Against Tau Toxicity via Activation of TRKB Signaling in ΔK280 TauRD-DsRed SH-SY5Y Cells , 2021, Frontiers in Aging Neuroscience.
[11] Yu Zou,et al. Unraveling the Influence of K280 Acetylation on the Conformational Features of Tau Core Fragment: A Molecular Dynamics Simulation Study , 2021, Frontiers in Molecular Biosciences.
[12] J. Loureiro,et al. Influence of in vitro neuronal membranes on the anti-amyloidogenic activity of gallic acid: Implication for the therapy of Alzheimer's disease. , 2021, Archives of biochemistry and biophysics.
[13] D. A. Bosco,et al. Mouse closed head traumatic brain injury replicates the histological tau pathology pattern of human disease: characterization of a novel model and systematic review of the literature , 2021, Acta Neuropathologica Communications.
[14] Sairam S. Mallajosyula,et al. Phosphorylation-Induced Structural Reorganization in Tau-Paired Helical Filaments. , 2021, ACS chemical neuroscience.
[15] C. White,et al. Chronic Traumatic Encephalopathy (CTE)-Type Neuropathology in a Young Victim of Domestic Abuse. , 2021, Journal of neuropathology and experimental neurology.
[16] Guanghong Wei,et al. Liquid-Liquid Phase Separation of Tau Protein Is Encoded at the Monomeric Level. , 2021, The journal of physical chemistry letters.
[17] D. Eliezer,et al. Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands. , 2021, International journal of biological macromolecules.
[18] R. Wennberg,et al. Association of Position Played and Career Duration and Chronic Traumatic Encephalopathy at Autopsy in Elite Football and Hockey Players , 2021, Neurology.
[19] Kevin F. Bieniek,et al. The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy , 2021, Journal of neuropathology and experimental neurology.
[20] Son Tung Ngo,et al. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. , 2021, Chemical reviews.
[21] S. Ramasamy,et al. EGCG impedes human Tau aggregation and interacts with Tau , 2020, Scientific Reports.
[22] A. McKee,et al. The Neuropathology of Chronic Traumatic Encephalopathy: The Status of the Literature , 2020, Seminars in Neurology.
[23] Bikash R. Sahoo,et al. High-Throughput Screening at the Membrane Interface Reveals Inhibitors of Amyloid-β. , 2020, Biochemistry.
[24] Guanghong Wei,et al. Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting Aβ42 Protofibril. , 2020, ACS chemical neuroscience.
[25] Junmei Wang,et al. Tau R3-R4 Domain Dimer of the Wild Type and Phosphorylated Ser356 Sequences. I. In Solution by Atomistic Simulations. , 2020, The journal of physical chemistry. B.
[26] N. Petrovsky,et al. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology , 2020, Neurobiology of Disease.
[27] H. Lashuel,et al. Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of Tau , 2020, The Journal of Biological Chemistry.
[28] Guanghong Wei,et al. Critical nucleus of Greek-key-like core of α-synuclein protofibril and its disruption by dopamine and norepinephrine. , 2019, Physical chemistry chemical physics : PCCP.
[29] S. Ghasemzadeh,et al. Inhibition of Tau Amyloid Fibril Formation by Folic Acid: in-vitro and theoretical studies. , 2019, International journal of biological macromolecules.
[30] N. Petrovsky,et al. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice , 2019, Scientific Reports.
[31] Sharad Gupta,et al. Nanobiocatalyst facilitated aglycosidic quercetin as a potent inhibitor of tau protein aggregation. , 2019, International journal of biological macromolecules.
[32] M. Pereira,et al. Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy. , 2019, Colloids and surfaces. B, Biointerfaces.
[33] C. Suter,et al. Chronic traumatic encephalopathy in two former Australian National Rugby League players , 2019, Acta Neuropathologica Communications.
[34] Qiuchen Zheng,et al. Inhibition of the Self-Assembly of Aβ and of Tau by Polyphenols: Mechanistic Studies , 2019, Molecules.
[35] Alexey G. Murzin,et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules , 2019, Nature.
[36] L. Meijer,et al. Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation , 2019, Front. Neurol..
[37] Guanghong Wei,et al. Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study. , 2019, ACS chemical neuroscience.
[38] R. Dinarvand,et al. Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation , 2018, DARU Journal of Pharmaceutical Sciences.
[39] D. Weaver,et al. Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation , 2018, Front. Neurosci..
[40] S. Moradi,et al. Effective suppression of the modified PHF6 peptide/1N4R Tau amyloid aggregation by intact curcumin, not its degradation products: Another evidence for the pigment as preventive/therapeutic "functional food". , 2018, International journal of biological macromolecules.
[41] C. Soto,et al. Inhibition of protein misfolding and aggregation by natural phenolic compounds , 2018, Cellular and Molecular Life Sciences.
[42] Hong Zhang,et al. Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease. , 2018, ACS nano.
[43] L. Buée,et al. Atypical, non-standard functions of the microtubule associated Tau protein , 2017, Acta neuropathologica communications.
[44] T. Walz,et al. Discovery and characterization of stable and toxic Tau/phospholipid oligomeric complexes , 2017, Nature Communications.
[45] D. Eisenberg,et al. Structure-based inhibitors of tau aggregation , 2017, Nature Chemistry.
[46] A. Saboury,et al. Vitamin B12 Inhibits Tau Fibrillization via Binding to Cysteine Residues of Tau. , 2017, ACS chemical neuroscience.
[47] Christine M Baugh,et al. Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football , 2017, JAMA.
[48] E. Gazit,et al. Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-Substituted Analogues. , 2017, Chemistry.
[49] Robin O Cleveland,et al. Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model , 2017, Alzheimer's & Dementia.
[50] W. Stewart,et al. Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers , 2016, Journal of neuropathology and experimental neurology.
[51] Seong Ae Bang,et al. Neuropsychological, Metabolic, and GABAA Receptor Studies in Subjects with Repetitive Traumatic Brain Injury. , 2016, Journal of neurotrauma.
[52] M. Choe. The Pathophysiology of Concussion , 2016, Current Pain and Headache Reports.
[53] Wayne A. Gordon,et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy , 2015, Acta Neuropathologica.
[54] J. Monti,et al. Gallotannins and Tannic Acid: First Chemical Syntheses and In Vitro Inhibitory Activity on Alzheimer's Amyloid β-Peptide Aggregation. , 2015, Angewandte Chemie.
[55] Chadwick M. Hales,et al. Late-stage CTE pathology in a retired soccer player with dementia , 2014, Neurology.
[56] U. Sengupta,et al. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.
[57] U. Sengupta,et al. Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury , 2013, The Journal of Biological Chemistry.
[58] D. Dougherty. The cation-π interaction. , 2013, Accounts of chemical research.
[59] L. Ji,et al. Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid. , 2013, Biochemistry.
[60] A. McKee,et al. The spectrum of disease in chronic traumatic encephalopathy. , 2013, Brain : a journal of neurology.
[61] Robin O Cleveland,et al. Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model , 2012, Science Translational Medicine.
[62] David Eisenberg,et al. Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.
[63] Douglas H. Smith,et al. Widespread Tau and Amyloid‐Beta Pathology Many Years After a Single Traumatic Brain Injury in Humans , 2012, Brain pathology.
[64] J. Terao,et al. Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. , 2011, Free radical biology & medicine.
[65] Jason T. Stevens,et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation , 2011, Nature.
[66] Ruth Nussinov,et al. Synergistic Interactions between Repeats in Tau Protein and Aβ Amyloids May Be Responsible for Accelerated Aggregation via Polymorphic States , 2011, Biochemistry.
[67] J. Bailes,et al. Chronic traumatic encephalopathy in a professional American wrestler , 2010, Journal of forensic nursing.
[68] A. McKee,et al. Mild traumatic brain injury: a risk factor for neurodegeneration , 2010, Alzheimer's Research & Therapy.
[69] R. Dror,et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.
[70] A. McKee,et al. Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury , 2009, Journal of neuropathology and experimental neurology.
[71] J. Simon,et al. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[72] M. Parrinello,et al. Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.
[73] V. Hornak,et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.
[74] E. Mandelkow,et al. Spectroscopic Approaches to the Conformation of Tau Protein in Solution and in Paired Helical Filaments , 2006, Neurodegenerative Diseases.
[75] Charles D. Smith,et al. Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.
[76] Berk Hess,et al. LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..
[77] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[78] Mark S. Gordon,et al. General atomic and molecular electronic structure system , 1993, J. Comput. Chem..
[79] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[80] P. Kollman,et al. Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .
[81] A T Tysvaer,et al. Soccer injuries to the brain , 1991, The American journal of sports medicine.
[82] Y. Ihara,et al. The car☐yl third of tau is tightly bound to paired helical filaments , 1988, Neuron.
[83] W. Kabsch,et al. Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.
[84] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[85] M. Parrinello,et al. Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .
[86] G. Will. “Punch Drunk” , 1939 .